NKTR-255 at 3.0/6.0 μg/kg

Drug identity checked against registry records

Also recorded as Polymer-conjugated interleukin (IL)-15 Receptor Agonist

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell LymphomaNCT05664217NKTRPhase 2, Phase 3Terminated2024-05-22Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.